{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:54:18Z","timestamp":1772477658353,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.remnie.2026.500285","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:26:12Z","timestamp":1771460772000},"page":"500285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA-PET as an emerging tool for response assessment in metastatic prostate cancer (mPC): Revolution and necessary evolution"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-4413","authenticated-orcid":false,"given":"N.","family":"\u00c1lvarez Mena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"G\u00f3mez Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Fierro Alanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Garc\u00eda-Talavera San Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Roteta Unceta Barrenechea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Men\u00e9ndez S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Montalv\u00e1 Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Badell Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Pe\u00f1aherrera Cepeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Carrera Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Quincoces Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rodr\u00edguez-Fraile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2026.500285_bib0005","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1148\/rg.2020200058","article-title":"Prostate-specific membrane antigen PET: therapy response assessment in metastatic prostate cancer","volume":"40","author":"Barbosa","year":"2020","journal-title":"Radiographics"},{"key":"10.1016\/j.remnie.2026.500285_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241258367","article-title":"Treatment response assessment in mCRPC: is PSMA-PET\/CT going to take the lead?","volume":"16","author":"Di Franco","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.remnie.2026.500285_bib0015","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3390\/biomedicines12102355","article-title":"Prognostic role of PSMA-targeted imaging in metastatic castration-resistant prostate cancer: an overview","volume":"12","author":"Caracciolo","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.remnie.2026.500285_bib0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s11912-025-01682-2","article-title":"The evolving role of PSMA-PET\/CT in prostate cancer management: an umbrella review of diagnostic restaging, therapeutic redirection, and survival impact","volume":"27","author":"Wang","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.remnie.2026.500285_bib0025","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an International multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0030","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.euo.2024.10.011","article-title":"Treatment response assessment according to updated PROMISE criteria in patients with metastatic prostate cancer using an automated imaging platform for identification, measurement, and temporal tracking of disease","volume":"8","author":"Benitez","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.remnie.2026.500285_bib0035","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1016\/j.acra.2024.12.027","article-title":"Prognostic value of response evaluation using PSMA PET\/CT in patients with metastatic prostate cancer (RECIP 1.0): a systematic review and meta-analysis","volume":"32","author":"Mourato","year":"2025","journal-title":"Acad Radiol"},{"key":"10.1016\/j.remnie.2026.500285_bib0040","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0045","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jmb.2007.12.066","article-title":"Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs","volume":"376","author":"Barinka","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1016\/j.remnie.2026.500285_bib0050","first-page":"81","article-title":"Prostate-specific membrane antigen expression in Normal and neoplastic tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.remnie.2026.500285_bib0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.remnie.2026.500285_bib0060","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/0008-5472.727.65.3","article-title":"Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness","volume":"65","author":"Ghosh","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.remnie.2026.500285_bib0065","doi-asserted-by":"crossref","first-page":"C975","DOI":"10.1152\/ajpcell.00506.2004","article-title":"Is prostate-specific membrane antigen a multifunctional protein?","volume":"288","author":"Rajasekaran","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.remnie.2026.500285_bib0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.116.181800","article-title":"68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience","volume":"58","author":"Hope","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0075","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2967\/jnumed.121.263006","article-title":"68Ga-PSMA PET\/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy","volume":"63","author":"Shagera","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0080","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","article-title":"177Lu-PSMA radioligand therapy for prostate cancer","volume":"58","author":"Fendler","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0085","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2967\/jnumed.123.265489","article-title":"68Ga-PSMA PET\/CT for response evaluation of 223Ra treatment in metastatic prostate cancer","volume":"64","author":"de Jong","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0090","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00259-018-3989-0","article-title":"18F-PSMA-1007 PET\/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0095","first-page":"995","article-title":"Treatment response evaluation in prostate cancer using PSMA PET\/CT","volume":"66","author":"Gafita","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0100","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2967\/jnumed.124.268818","article-title":"The role of PSMA PET parameters as biomarkers for response to PSMA-targeted radiopharmaceutical therapy","volume":"66","author":"Murthy","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0105","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","article-title":"Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy","volume":"45","author":"Seitz","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153768","article-title":"Clinical applications of PSMA PET examination in patients with prostate cancer","volume":"14","author":"Rasul","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.remnie.2026.500285_bib0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.remnie.2026.500285_bib0120","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.remnie.2026.500285_bib0125","doi-asserted-by":"crossref","first-page":"S970","DOI":"10.1016\/j.annonc.2024.08.1689","article-title":"Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET\/CT for response evaluation: analysis from the PRINCE trial","volume":"35","author":"Hofman","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.remnie.2026.500285_bib0130","author":"Klaassen"},{"key":"10.1016\/j.remnie.2026.500285_bib0135","series-title":"A study of 177Lu-PSMA-617 plus pembrolizumab in participants with metastatic castration-resistant prostate cancer (PRINCE) [Internet]","year":"2023"},{"key":"10.1016\/j.remnie.2026.500285_bib0140","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0145","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2967\/jnumed.120.260836","article-title":"Assessing response to [177Lu]PSMA radioligand therapy using modified PSMA PET progression criteria","volume":"62","author":"Michalski","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0150","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0155","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.remnie.2026.500285_bib0160","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1007\/s00259-023-06382-2","article-title":"Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images","volume":"50","author":"Kendrick","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0165","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0170","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0175","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of Lu-labeled PSMA-targeted radioligand therapy (Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0180","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [\u00b9\u2077\u2077Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.remnie.2026.500285_bib0185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [\u00b9\u2077\u2077Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.remnie.2026.500285_bib0190","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00259-025-07632-1","article-title":"Refining the clinical utility of [177Lu]Lu[225Ac]Ac-PSMA tandem RLT in patients with metastatic castration-resistant prostate cancer","volume":"53","author":"Widjaja","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0195","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2967\/jnumed.122.264857","article-title":"A single-arm, low-dose, prospective study of Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"64","author":"Wang","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0200","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","article-title":"Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.remnie.2026.500285_bib0205","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2967\/jnumed.123.267014","article-title":"Development of a visually calculated SUVmean (HIT score) on screening PSMA PET\/CT to predict treatment response to 177Lu-PSMA therapy: comparison with quantitative SUVmean and patient outcomes","volume":"65","author":"Swiha","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0210","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2967\/jnumed.123.267234","article-title":"RECIP 1.0 predicts progression-free survival after [177Lu]Lu-PSMA radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer","volume":"65","author":"Gafita","year":"2024","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.remnie.2026.500285_bib0215","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1007\/s00259-025-07592-6","article-title":"RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer","volume":"53","author":"Molin","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.remnie.2026.500285_bib0220","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00259-025-07613-4","article-title":"[177Lu]Lu-PSMA SPECT\/CT for early response assessment using quantitative RECIP 1.0","volume":"53","author":"Kassas","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0225","first-page":"1054","article-title":"Evidence-based clinical protocols to monitor efficacy of [177Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer using real-world data","volume":"66","author":"Unterrainer","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0230","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0235","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12149-024-01990-w","article-title":"Evaluating response to radium-223 using 68Ga-PSMA PET\/CT imaging in patients with metastatic castration-resistant prostate cancer","volume":"39","author":"Shagera","year":"2025","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0240","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.remnie.2026.500285_bib0245","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0250","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-022-05970-y","article-title":"Flare on [18F]PSMA-1007 PET\/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-na\u00efve metastatic prostate cancer patients","volume":"50","author":"Malaspina","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0255","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00259-019-04635-7","article-title":"Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET\/MRI in men with treatment-na\u00efve prostate cancer","volume":"47","author":"Ettala","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0260","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2967\/jnumed.124.268340","article-title":"Exploring the flare phenomenon in patients with castration-resistant prostate cancer: enzalutamide-induced PSMA upregulation observed on PSMA PET","volume":"66","author":"van der Gaag","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0265","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.123.265874","article-title":"PSMA PET\/CT for response assessment and overall survival prediction in patients with metastatic castration-resistant prostate cancer treated with androgen receptor pathway inhibitors","volume":"64","author":"Shagera","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111774","article-title":"PSMA PET\/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients","volume":"181","author":"Kleiburg","year":"2024","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.remnie.2026.500285_bib0275","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s00259-024-06887-4","article-title":"Correlation of [68Ga]Ga-PSMA PET\/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients","volume":"52","author":"Giunta","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0280","first-page":"528","article-title":"PSMA PET\/CT to evaluate response to SBRT for prostate cancer bone metastases","volume":"26","author":"Sadetski","year":"2021","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.remnie.2026.500285_bib0285","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s12094-022-03002-7","article-title":"Metabolic response after 68Ga-PSMA-PET\/CT-directed IGRT\/SBRT for oligometastases prostate cancer","volume":"25","author":"Gawish","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.remnie.2026.500285_bib0290","article-title":"PSMA response evaluation in follow-up PSMA-PET\/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer","volume":"54","author":"Zang","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.remnie.2026.500285_bib0295","article-title":"Prostate-specific membrane antigen PET response associates with metastasis-free survival after stereotactic ablative radiation in oligometastatic prostate cancer","volume":"9","author":"Sutera","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.remnie.2026.500285_bib0300","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.remnie.2026.500285_bib0305","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13550-019-0554-1","article-title":"[68Ga]Ga-PSMA-11 PET\/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?","volume":"9","author":"Kuten","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.remnie.2026.500285_bib0310","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1016\/j.remnie.2026.500285_bib0315","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","article-title":"Focal unspecific bone uptake on [(18)F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging","volume":"48","author":"Grunig","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0320","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500285_bib0325","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s00259-017-3725-1","article-title":"Development of standardized Image interpretation for 68Ga-PSMA PET\/CT to detect prostate cancer recurrent lesions","volume":"44","author":"Fanti","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2026.500285_bib0330","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","article-title":"Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer","volume":"1","author":"Aggarwal","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.remnie.2026.500285_bib0335","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","article-title":"Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer","volume":"8","author":"Luckerath","year":"2018","journal-title":"EJNMMI Res"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808926000315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808926000315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:56:11Z","timestamp":1772474171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808926000315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":67,"alternative-id":["S2253808926000315"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2026.500285","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA-PET as an emerging tool for response assessment in metastatic prostate cancer (mPC): Revolution and necessary evolution","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2026.500285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2026.500285","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500285"}}